Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C162563
http://purl.obolibrary.org/obo/NCIT_C162563
|
|---|---|
| Preferred Name | Lutetium Lu-177 Rituximab |
| Definitions |
A radioconjugate composed of rituximab, a recombinant chimeric murine/human immunoglobulin G1 (IgG1) antibody directed against the CD20 antigen, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, the rituximab moiety targets and binds to CD20 expressed on tumor cells and delivers a cytotoxic dose of beta radiation to CD20-expressing cells. CD20 is expressed on the surface of pre-B and mature B-lymphocytes and is overexpressed in a variety of B-cell malignancies.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A radioconjugate composed of rituximab, a recombinant chimeric murine/human immunoglobulin G1 (IgG1) antibody directed against the CD20 antigen, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, the rituximab moiety targets and binds to CD20 expressed on tumor cells and delivers a cytotoxic dose of beta radiation to CD20-expressing cells. CD20 is expressed on the surface of pre-B and mature B-lymphocytes and is overexpressed in a variety of B-cell malignancies. |
|---|---|
| prefLabel | Lutetium Lu-177 Rituximab
|
| label | Lutetium Lu-177 Rituximab
|
| NCI_META_CUI | CL971073
|
| code | C162563
|
| prefixIRI | NCIT:C162563
|
| in_subset | |
| Preferred_Name | Lutetium Lu-177 Rituximab
|
| Maps_To | Lutetium Lu-177 Rituximab
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |